MAIN CONTENT
“Not a mini-FDA”
Li noted that while many places in Asia, such as mainland China, Singapore and Japan, established drug regulators long ago, Hong Kong has distinctive advantages and does not intend to copy anyone's model – including the US Food and Drug Administration.
We are not going to be a mini-FDA, nor a miniature version of any regulatory body in the world.
The US regulator is strong because of its pharmaceutical industry, he said, with both sides pushing each other forward, and the mainland industry could have a similar symbiotic relationship with Hong Kong's regulator. With 34% of global innovative drug pipelines now coming from mainland China, he said, it is clear where Hong Kong's advantages lie.
A bridge for Chinese medicines to the world
Educated at Peking Union Medical College and Johns Hopkins University, Li has 30 years of drug development and regulatory experience, having served at the FDA and several multinational drug companies. He was selected after a global recruitment exercise that drew more than 20 applicants.
















